Clinical Trial Update: Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial update on cord blood-derived CAR-NK cells targeting CD19 for refractory/recurrent central nervous system lymphoma; the study is currently enrollin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Cord blood-derived CAR-NK cells targeting CD19 (CAR-NK cells (CD19-targeted) derived from cord blood)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Refractory/Recurrent Central Nervous System Lymphoma | Phase 1 | Status: ENROLLING_BY_INVITATION